|
1
|
Larue L and Bellacosa A:
Epithelial-mesenchymal transition in development and cancer: Role
of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene.
24:7443–7454. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hosono S, Kajiyama H, Terauchi M, Shibata
K, Ino K, Nawa A and Kikkawa F: Expression of Twist increases the
risk for recurrence and for poor survival in epithelial ovarian
carcinoma patients. Br J Cancer. 96:314–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang Y, Ahn YH, Chen Y, Tan X, Guo L,
Gibbons DL, Ungewiss C, Peng DH, Liu X, Lin SH, et al: ZEB1
sensitizes lung adenocarcinoma to metastasis suppression by PI3K
antagonism. J Clin Invest. 124:2696–2708. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wu WS, Heinrichs S, Xu D, Garrison SP,
Zambetti GP, Adams JM and Look AT: Slug antagonizes p53-mediated
apoptosis of hematopoietic progenitors by repressing puma. Cell.
123:641–653. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Spaderna S, Schmalhofer O, Wahlbuhl M,
Dimmler A, Bauer K, Sultan A, Hlubek F, Jung A, Strand D, Eger A,
et al: The transcriptional repressor ZEB1 promotes metastasis and
loss of cell polarity in cancer. Cancer Res. 68:537–544. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sanchez-Tilló E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hashiguchi M, Ueno S, Sakoda M, Iino S,
Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et
al: Clinical implication of ZEB-1 and E-cadherin expression in
hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siebzehnrubl FA, Silver DJ, Tugertimur B,
Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT,
Kupper MD, Neal D, et al: The ZEB1 pathway links glioblastoma
initiation, invasion and chemoresistance. EMBO Mol Med.
5:1196–1212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Holschneider CH and Berek JS: Ovarian
cancer: Epidemiology, biology, and prognostic factors. Semin Surg
Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Prat J: New insights into ovarian cancer
pathology. Ann Oncol. 23:(Suppl 10). x111–x117. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Groen RS, Gershenson DM and Fader AN:
Updates and emerging therapies for rare epithelial ovarian cancers:
One size no longer fits all. Gynecol Oncol. 136:373–383. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeppernick F and Meinhold-Heerlein I: The
new FIGO staging system for ovarian, fallopian tube, and primary
peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen VW, Ruiz B, Killeen JL, Coté TR, Wu
XC and Correa CN: Pathology and classification of ovarian tumors.
Cancer. 97:(10 Suppl). S2631–S2642. 2003. View Article : Google Scholar
|
|
17
|
Kajiyama H, Shibata K, Mizuno M, Umezu T,
Suzuki S, Yamamoto E, Fujiwara S, Kawai M, Nagasaka T and Kikkawa
F: Long-term clinical outcome of patients with recurrent epithelial
ovarian carcinoma: Is it the same for each histological type? Int J
Gynecol Cancer. 22:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kikkawa F, Nawa A, Ino K, Shibata K,
Kajiyama H and Nomura S: Advances in treatment of epithelial
ovarian cancer. Nagoya J Med Sci. 68:19–26. 2006.PubMed/NCBI
|
|
19
|
Yoshikawa N, Kajiyama H, Mizuno M, Shibata
K, Kawai M, Nagasaka T and Kikkawa F: Clinicopathologic features of
epithelial ovarian carcinoma in younger vs. older patients:
Analysis in Japanese women. J Gynecol Oncol. 25:118–123. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kajiyama H, Shibata K, Terauchi M, Ino K,
Nawa A and Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the
enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int
J Cancer. 122:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Terauchi M, Kajiyama H, Yamashita M, Kato
M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, et
al: Possible involvement of TWIST in enhanced peritoneal metastasis
of epithelial ovarian carcinoma. Clin Exp Metastasis. 24:329–339.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Spoelstra NS, Manning NG, Higashi Y,
Darling D, Singh M, Shroyer KR, Broaddus RR, Horwitz KB and Richer
JK: The transcription factor ZEB1 is aberrantly expressed in
aggressive uterine cancers. Cancer Res. 66:3893–3902. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen D, Wang J, Zhang Y, Chen J, Yang C,
Cao W, Zhang H, Liu Y and Dou J: Effect of down-regulated
transcriptional repressor ZEB1 on the epithelial-mesenchymal
transition of ovarian cancer cells. Int J Gynecol Cancer.
23:1357–1366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sahai E and Marshall CJ: Differing modes
of tumour cell invasion have distinct requirements for Rho/ROCK
signalling and extracellular proteolysis. Nat Cell Biol. 5:711–719.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Wever O, Demetter P, Mareel M and
Bracke M: Stromal myofibroblasts are drivers of invasive cancer
growth. Int J Cancer. 123:2229–2238. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD
and Wang LH: Twist transcriptionally up-regulates AKT2 in breast
cancer cells leading to increased migration, invasion, and
resistance to paclitaxel. Cancer Res. 67:1979–1987. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wellner U, Schubert J, Burk UC,
Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D,
zur Hausen A, et al: The EMT-activator ZEB1 promotes tumorigenicity
by repressing stemness-inhibiting microRNAs. Nat Cell Biol.
11:1487–1495. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Richard G, Dalle S, Monet MA, Ligier M,
Boespflug A, Pommier RM, de la Fouchardière A, Perier-Muzet M,
Depaepe L, Barnault R, et al: ZEB1-mediated melanoma cell
plasticity enhances resistance to MAPK inhibitors. EMBO Mol Med.
8:1143–1161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sugiyama T, Kamura T, Kigawa J, Terakawa
N, Kikuchi Y, Kita T, Suzuki M, Sato I and Taguchi K: Clinical
characteristics of clear cell carcinoma of the ovary: A distinct
histologic type with poor prognosis and resistance to
platinum-based chemotherapy. Cancer. 88:2584–2589. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimada M, Kigawa J, Ohishi Y, Yasuda M,
Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T and Kaku T:
Clinicopathological characteristics of mucinous adenocarcinoma of
the ovary. Gynecol Oncol. 113:331–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
